| Ytd | 14.60% | |
| 1y | -51.13% |
| Open | 0.72 | Prev Close | 0.70 | Low | 0.71 | High | 0.78 | Mkt Cap | 15.76M |
| Vol | 170.33K | Avg Vol | 389.85K | EPS | -1.04 | P/E | -0.73 | Forward P/E | -1.43 |
| Beta | 1.90 | Short Ratio | 1.75 | Inst. Own | 6.08% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.69 | 200-d Avg | 0.70 | 1yr Est | 6.50 |
COCH News
Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.07 per share versus the Zacks Consen
Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Repo
Envoy Medical, Inc. (COCH) doesn't possess the right combination of the two key ingredients for a li
White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("
HC Wainwright & Co. analyst Yi Chen reiterates Envoy Medical (NASDAQ:COCH) with a Buy and mai
Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-im
Envoy Medical reported improved 12-month hearing results for its Acclaim cochlear implant as its piv
Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and S
Termination Reflects Company's Confidence in Current Capital Position White Bear Lake, Minnesota--(N
White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("
White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a
Australian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in
Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising
Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Qu
Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareho
Company Remains on Schedule for PMA Submission to FDA White Bear Lake, Minnesota--(Newsfile Corp. -
Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR
Received FDA approval to expand fully implanted Acclaim® Cochlear Implant Pivotal Clinical Trial to
Competitive Technologies (OTCMKTS:CTTC - Get Free Report) and Envoy Medical (NASDAQ: COCH - Get Free
First Cochlear Implant Company to Announce Completed Enrollment of a U.S. Pivotal Clinical Trial for
White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2026) - Envoy Medical® Inc. (NASDAQ: COCH
White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH
TearLab (OTCMKTS:TEAR - Get Free Report) and Envoy Medical (NASDAQ: COCH - Get Free Report) are both
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after